The Oncology Journal Club Episode 5: Cachexia, Gender Equity and Manels, Quick Bites, Special Guest Dr Christoper Steer and much more…

Google+ Pinterest LinkedIn Tumblr +

The Oncology Podcast, brought to you by www.oncologynews.com.au, is proud to present the next episode of The Oncology Journal Club.

Our latest Journal Club episode is hosted by Professor Eva Segelov, from Monash University in Melbourne. She is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Belgium.

This week Professor Eva Segelov  gets us started with a presentation on cachexia and Craig chats with Dr Christopher Steer, a Geriatric Oncology specialist, about papers presented at the recent ASCO meeting, including Kheng Soo’s paper on “Integrating Geriatric Assessment and Management Into Cancer Care” which Christopher hails as ‘The Rolls Royce Model of Cancer Care in Older Adults’.

As Craig notes, this represents half our patient population so it’s a very important issue that cuts across all tumour streams so I hope you find the segment valuable.

Hans presents some fascinating translational studies from Nature and we also have not 1 not 2 but 3 new segments this week… you may have noticed a little competitiveness between the team so of course they had to have one each!

We hope you enjoy another entertaining episode of The Oncology Journal Club. As ever, the links to all the papers discussed today are available below.

About The Oncology Journal Club

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and studies presented at key meetings to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

We hope you enjoy listening and find this a valuable resource. Please let us know what you think!

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

 

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

Dr Christopher Steer

Christopher Steer

Dr Steer is a medical oncologist working at Border Medical Oncology in the recently completed Albury Wodonga Regional Cancer Centre. He is a senior lecturer at the UNSW rural clinical school, Albury campus.

Christopher was the inaugural chair of the geriatric oncology interest group of the Clinical Oncological Society of Australia (COSA).  He is actively involved in the International Society of Geriatric Oncology (SIOG) and was chair of the scientific committee of the annual scientific meeting in Prague in November 2015. He is an editorial board member of the Journal of Geriatric Oncology and the European Journal of Surgical Oncology. Christopher is chair of the geriatric oncology interest group of the Multinational Association for Supportive Care in Cancer (MASCC).

Christopher is the current president of the Private Cancer Physicians of Australia (PCPA) and is a member of the MOGA/PCPA cancer drugs working group.

Christopher is on the Australian Cancer Symptom Trials (CST) research group management advisory committee.

Christopher is a principle investigator at the Border Medical Oncology research unit (BMORU). The BMORU has been recognized for innovation in clinical research particularly in delivering care to a rural/regional population. Christopher has led a pilot project of supportive care in older adults with cancer with funding from Cancer Australia. He is currently investigating the feasibility of an electronic rapid fitness assessment in older adults with cancer in collaboration with the Memorial Sloan Kettering Cancer Centre in New York with research funding from the AWRCC Trust.

Other research projects include supervision of UNSW medical students as they conduct Independent Learning Projects.

Twitter: @drcbsteer

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of www.oncologynews.com.au. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Christopher Steer and Graham Knowles.

 

 


This Week’s Papers:

Main Papers:

  1. Roeland, Eric J.  et al. Management of Cancer Cachexia: ASCO Guideline. JCO.20.00611 Journal of Clinical Oncology. Access online here.
  2. Lewiss, Resa E. et al. Is Academic Medicine Making Mid-Career Women Physicians Invisible? | Journal of Women’s Health. Access online here.
  3. AbdulJabbar, K. et al. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat Med (2020). Access online here.
  4. Brastianos, P.K. et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med (2020). Access online here.

Guest Interview with Dr Christopher Steer – Geriatric Oncology Presentations from the ASCO 2020 Virtual Meeting:

  1. Soo, Wee-Kheng et al. Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. J Clin Oncol 38: 2020 (suppl; abstr 12011). Access online here
  2. Discussant: Heidi D. Klepin, MD, MS. Get Up and Go: Impact of Geriatric Assessment–Driven Interventions. Access video here (ASCO Login Required).
  3. Li, Daneng et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: A randomized controlled trial. J Clin Oncol 38: 2020 (suppl; abstr 12010). Access online here.

Quick Bites:

  1. Rao, Sheela et al. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020 Jun 12. Access online here.
  2. Navari, Rudolph M. et al. Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol. 2020;6(6):895–899. Access online here
  3. Kiyota, Naomi et al. Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). J Clin Oncol 38: 2020 (suppl; abstr 6502). Access online here.
  4. Frenel, Jean-Sebastien et al. Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). J Clin Oncol 38: 2020 (suppl; abstr 6070). Access online here.
  5. Gilbert, Lucy et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer. J Clin Oncol 38: 2020 (suppl; abstr 6004). Access online here.

PBS Update:

  1. Novel triplet therapy for newly diagnosed multiple myeloma patients now PBS listed. Oncology News, June 2020. Access here (password protected – contact info@oncologynetwork.com.au for information.)

Investor Update:

  1. Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer
  2. Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer

FDA Approval:

  1. Gardasil 9 for Head and Neck Cancer. Access FDA Announcement here.

 

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.